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Temozolomide (TMZ) is the standard of care chemotherapeutic agent used in the
treatment of glioblastoma multiforme. Cytotoxic O6-methylguaine lesions formed by
TMZ are repaired by O6-methyl-guanine DNA methyltransferase (MGMT), a DNA repair
protein that removes alkyl groups located at the O6-position of guanine. Response
to TMZ requires low MGMT expression and functional mismatch repair. Resistance
to TMZ conferred by MGMT, and tolerance to O6-methylguanine lesions conferred
by deficient MMR severely limit TMZ clinical applications. Therefore, development
of new TMZ derivatives that can overcome TMZ-resistance is urgent. In this study,
we investigated the anti-tumor mechanism of action of two novel TMZ analogs:
C8-imidazolyl (377) and C8-methylimidazole (465) tetrazines. We found that analogs
377 and 465 display good anticancer activity against MGMT-overexpressing glioma
T98G and MMR deficient colorectal carcinoma HCT116 cell lines with IC50 value
of 62.50, 44.23, 33.09, and 25.37µM, respectively. Analogs induce cell cycle
arrest at G2/M, DNA double strand break damage and apoptosis irrespective of
MGMT and MMR status. It was established that analog 377, similar to TMZ, is
able to ring-open and hydrolyze under physiological conditions, and its intermediate
product is more stable than MTIC. Moreover, DNA adducts of 377 with calf
thymus DNA were identified: N7-methylguanine, O6-methylguanine, N3-methyladenine,
N3-methylthymine, and N3-methylcytidine deoxynucleotides. We conclude that C8
analogs of TMZ share a mechanism of action similar to TMZ and are able to methylate
DNA generating O6-methylguanine adducts, but unlike TMZ are able at least in part to
thwart MGMT- and MMR-mediated resistance.
Keywords: glioblastoma, colorectal carcinoma, O6-methylguanine-DNA methyltransferase, apoptosis, DNA
adducts
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INTRODUCTION
Temozolomide (TMZ), an oral alkylating agent, has been
administered in conjunction with radiation as the standard of
care for glioblastoma multiforme (GBM) treatment (1). TMZ is
an imidazotetrazine prodrug that is able to cross the blood–brain
barrier (BBB) (2). Under normal physiological conditions, TMZ
spontaneously hydrolyzes to form the active intermediate 3-
methyl-(triazen-1-yl) imidazole-4-carboxamide (MTIC). MTIC
rapidly breaks down to form the reactive methyldiazonium ion
(diazomethane) which reacts with nucleophilic groups on DNA,
resulting in DNA methylation (3). Approximately 70% of the
methyl groups are located on the N7 of guanine (N7-G), 10%
on N3-adenine (N3-A), and 5% at O6-guanine (O6-G) sites
(2, 3). Interestingly, TMZ exerts cytotoxicity mainly through
O6-methylguanosine (O6-MeG) which triggers futile cycles of
mismatch repair (MMR), stalled replication forks and lethal DNA
double-strand breaks, while N7- and N3-methyl purines are
rapidly repaired by base excision repair (BER) (4, 5). However,
O6-MeG lesions can be repaired by O6-methyl-guanine DNA
methyltransferase (MGMT), a DNA repair protein that removes
alkyl groups located at the O6-position of guanine (6). Thus,
response to TMZ requires low MGMT expression and intact
MMR (7, 8).
Resistance to TMZ conferred by MGMT and tolerance to
O6-MeG in the presence of defective MMR limits TMZ clinical
applications. Therefore, strategies have been devised to reduce
resistance and enhance response to TMZ, including inhibition
of DNA repair mechanisms which contribute to TMZ resistance.
For example, combining MGMT inhibitors, which consume
MGMT and preventO6-MeG repair, with TMZ sensitizes tumors
to TMZ treatment (9). However, myelosuppression limits the
use of MGMT inhibitors and alkylating agent combination
chemotherapy (10). Other DNA repair (BER) protein inhibitors
have been used in combination with TMZ to treat cancer, such as
poly ADP-ribose polymerase (PARP) inhibitors. Although PARP
inhibitors (in combination with TMZ) are better tolerated than
MGMT inhibitors, myelosuppression, and liver toxicity still cause
clinical concern (11, 12).
An alternative strategy is the development of TMZ analogs
which can overcome TMZ-resistance. A series of TMZ
derivatives has been synthesized and the anticancer activity
was investigated in vitro. N3-substituted TMZ analogs were
developed and several derivatives exhibited an activity against
TMZ-resistant tumor cells in vitro (13–16). In contrast, C8-
substituted TMZ analogs have rarely been reported and
compounds mechanisms of action remain unclear (17). In
this study, the anti-tumor effects of two novel C8-substituted
TMZ derivatives have been investigated in TMZ-resistant tumor
models in vitro. The C8 carboxamide was replaced by imidazolyl
(377) and methylimidazole (465) groups, respectively (Figure 1).
377 and 465 analogs demonstrated good anticancer activity
against MGMT overexpressing glioma T98G and MMR deficient
colorectal carcinoma HCT116 cell lines. Moreover, 377 and
465 were able to arrest the cell cycle at G2/M, evoke DNA
damage, and trigger apoptosis in T98G GBM and HCT116 CRC
cells, irrespective of MGMT and MMR status. The mechanism
FIGURE 1 | Chemical structures of TMZ, 377, and 465.
by which analog 377 exacts DNA damage, and specific DNA
lesions produced have been identified. Like TMZ, analog
377 ring-opens and hydrolyzes under physiological conditions
leading to DNA adducts formation N7-methylguanine (N7-
MeG), O6-methylguanine (O6-MeG), N3-methyladenine (N3-
MeA), N3-methylthymine (N3-MeT), and N3-methylcytidine
(N3-MeC) deoxynucleotides.
MATERIALS AND METHODS
Chemicals
TMZ was provided by Schering-Plow Research Institute
(Kenilworth, NJ, USA). New analogs, synthesized at Pharminox
Ltd, BioCity, Nottingham, UK, were prepared as 100mM stock
solutions in dimethyl sulfoxide (DMSO) and stored at −20◦C.
Reagents, unless specified otherwise, originated from Sigma-
Aldrich Ltd.
Cell Lines and Culture Conditions
SNB19V (vector) and isogenic MGMT-transfected SNB19M
human GBM cell lines were provided by Schering-Plow. Cells
were cultured in RPMI 1640 medium supplemented with 2%
glutamine, 1% non-essential amino acids, 50µg/ml gentamicin,
400 g/ml G418 (geneticin), and 10% fetal bovine serum (FBS).
HCT116 (hMLH1-) and HT29 CRC cells obtained from the
American Type Culture Collection (ATCC), were maintained
in RPMI 1640 medium supplemented with 10% FBS. T98G
GBM cells (sourced from the ATCC) were grown in DMEM
medium supplemented with 10% FBS. Cells were incubated in
a humidified atmosphere of 95% air and 5% CO2 at 37
◦C.
MTT Assay
Cells were seeded into wells at a density of 4 × 103 per
well in 96-well plates and allowed to attach overnight. TMZ,
377, or 465 dilutions were prepared in culture medium
from 100mM stock solutions and final well-concentrations
between 0.1 and 1,000µM were achieved (n = 3). Following
3 days of incubation (37◦C, 5% CO2). Sterile-filtered 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
(20 µl; 5 mg/ml in phosphate buffered saline) was added
to each well (final concentration 0.4 mg/ml). Plates were re-
incubated for 4 h allowing metabolism of MTT by viable cells
to insoluble formazan crystals. Medium and unconverted MTT
were aspirated and DMSO (150 µl) was added to each well
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to ensure complete formazan solubilization, absorbance was
read on a BioTek Synergy H1 microplate reader (490 nm).
Compounds concentrations causing 50% inhibition (IC50) values
were calculated by interpolation.
Clonogenic Assay
Exponentially growing cells were seeded in triplicate at a density
of 300 cells per well in 6-well plates and allowed to attach
overnight before introduction of TMZ (final concentrations 5,
10, 100, 500, and 1,000µM), 377 (final concentrations 20, 40,
60, 80, and 100µM), 465 (final concentrations 10, 20, 30, 40, and
50µM). Control wells received vehicle alone.
After 16 h exposure, media were aspirated, cells washed,
and TMZ-free media introduced. Plates were incubated for
11 days at 37◦C in an atmosphere of 5% CO2. Cells were
washed (3× in phosphate buffered saline), fixed with pre-chilled
methanol (100%; 20min), stained with 0.5% methylene blue in
1:1 methanol/H2O (v/v) for 10min, washed thoroughly in dH2O
and air-dried. Cell colonies containing >50 cells were counted
and IC50 values were calculated by interpolation.
Detection of γ-H2AX Foci
HCT116 and T98G cells (2 × 105) were seeded onto coverslips
in 6-well plates and incubated overnight, before being exposed
to 377 (50 and 100µM) and 465 (20 and 50µM) for 3, 6, 9,
12, and 24 h. Cells were fixed with ice cold acetone, rinsed with
PBS and blocked with 3% BSA and treated with 0.3% Triton-X in
PBS for 30min at room temperature. Cells were incubated with
primary antibody (1◦ Ab) recognizing phosphorylated H2AX
(γH2AX; Cell Signaling; overnight at 4◦C), then fluorescence-
conjugated Alexa Fluor 488 secondary (2◦) Ab (Life technologies;
8µg/ml diluted in antibody dilution buffer) for 60min at room
temperature protected from light. Nuclei were stained with
0.1µg/ml DAPI. Cells were observed by immunofluoroscence
microscopy (Nikon, Japan; original magnification 100×) and
images captured.
Pulsed-Field Gel Electrophoresis
Cells (2 × 106) were seeded onto coverslips in plates and
incubated overnight before treatment with 100µM TMZ,
100µM 377, and 50µM 465 for 24 and 48 h. Cells (6× 105) were
collected from each sample and small agarose plugs embedded
with cells were prepared. The small plugs were then digested with
Proteinase K reaction buffer (10mM Tris, 20mM NaCl, 50mM
EDTA, and 1 mg/ml Proteinase K; 50◦C, 48 h). The plugs were
washed four times in 50ml of wash buffer (20mM Tris, pH 8.8,
50mM EDTA) for 30min each at room temperature with gentle
agitation. DNA fragments in plugs were separated on 1% w/v
agarose gels in 0.5× Tris/borate/ethylenediaminetetraacetic acid
(TBE) buffer at 14◦C using a CHEF DRII apparatus (Bio-Rad)
with 6 V/cm, pulsed from 60 to 120 s for 24 h. The gels were
stained with ethidium bromide (EB). Images were recorded using
a gel imager (BIOGEN).
Western Blot Analysis
Cells were lysed in RIPA lysis buffer (25mM Tris HCl
(pH 7.5), 2.5mM EDTA, 2.5mM EGTA, 20mM NaF, 1mM
Na3VO4, 100mM NaCl, 20mM sodium -glycerophosphate,
10mM sodium pyrophosphate, 0.5% triton X-100) supplemented
with a protease inhibitor cocktail (Roche). Cellular proteins
(30 µg) were separated by SDS-PAGE, and electro-transferred
onto PVDF membranes. Membranes were blocked in Tris-
buffered saline (TBS) containing 5% milk and 0.1% Tween-
20 at room temperature. Membranes were incubated with 1◦
Abs (γH2AX, actin, tubulin, PARP, and caspase 3, from Cell
Signaling) overnight at 4◦C; membranes were washed at room
temperature before incubation with 2◦ Ab (GE) conjugated
with horseradish peroxidase for 1 h. All antibodies were diluted
according to the manufacturer’s recommendations. Detection
was performed with Super Signal Chemiluminescent reagent
according to the manufacturer’s protocol (Tanon, China).
Alkaline Agarose Gel Electrophoresis
TMZ, 377, and 465 (1, 10, and 20µM) were mixed with
1.5 µg pEGFP-N1 plasmid in 40 µl buffer (3mM NaCl, 1mM
Na3PO4, and 1mM EDTA, pH 8.0) and reacted at 37
◦C for 2 h.
Then restriction endonuclease BamHI was added to linearize
the plasmid, and DNA was precipitated with ethanol. DNA
precipitates were dissolved by 1× alkaline agarose electrophoresis
buffer (10× alkaline agarose electrophoresis buffer: 500mM
NaOH and 10mM EDTA, pH 8.0). The desired amount of
powdered agarose was thawed in a measured amount of water,
cooled to ∼55◦C, and 0.1× volume of 10× basic agarose
electrophoresis buffer was added. Then 20 µl dissolved DNA was
mixed with 4 µl 6× basic loading buffer (300mM NaOH, 6mM
EDTA, 18% Ficoll 400, 0.15% bromocresol green, 0.25% xylene
cyanol). Samples were loaded and electrophoresed at a maximum
of 5 V/cm at 4◦C until the bromocresol green hadmigrated∼two-
thirds of the gel length. The gels were placed in a neutralizing
solution (1.5M NaCl and 1mM Tris-HCl, pH 7.6) and soaked
for 45min at room temperature. The gels were stained with EB
and final results recorded using a gel imager (BIOGEN).
Cell Cycle Analysis
Exponentially growing cells were harvested and seeded in 6-well
plates (2 × 105 cells/well; 2ml medium). Cells were incubated
overnight, then treated with TMZ (100µM), 377 (50 and
100µM), and 465 (20 and 50µM). Following incubation (24, 48,
72, and 96 h), attached and floating cells were pooled and pelleted
by centrifugation (1,200 rpm, at 4◦C, 5min). Pellets were washed
(PBS), cells were re-suspended in 0.3ml hypotonic fluorochrome
solution (0.1% sodium citrate, 0.1% Triton X-100, 50µg/ml PI,
and 0.1 mg/ml ribonuclease A) and stored overnight at 4◦C in
the dark. Fluorescence of PI-stained DNA was detected on a BD
C6 cytometer and data were analyzed using C6 software.
Mitochondrial Membrane Potential Assay
Cells (2 × 105) were seeded in 6-well plates and incubated
overnight, then cells were treated with 10, 20, and 50µM 465 for
9 h. The experimental procedure was carried out according to the
JC-10 Mitochondrial Membrane Potential Assay Kit instructions
(Sangon, China). Cells (5 × 105 per tube) were centrifuged and
pellets suspended in 500 µl of JC-10 dye loading solution and
incubated for 40min at room temperature or 37◦C in a 5% CO2
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incubator. JC-10 monomers and J-aggregates were detected by
flow cytometry on FL1 and FL2 channels, respectively. Data were
analyzed using C6 software.
Sample Extraction and Purification
Calf thymus DNA (40 µl; 0.2mg) and 40 µl 377 (0.2mg) were
dissolved in 120 µl NaCl (15mM) and incubated in 37◦C for
24 h. The reaction mixture was then cooled to room temperature,
and extracted with 250 µl diethyl ether 4× with centrifugation.
The extracted DNA was precipitated with 100 µl 3M sodium
acetate solution (pH 5.2) and 1ml ice-cold ethanol. The solution
was then put on ice for 30min and centrifuged at 4◦C at
10,000 g for 15min. The resulting DNA pellet was washed twice
with 100 µl ethanol (70%) and dried under vacuum. The dried
DNA pellet was re-dissolved in 100 µl 2mM magnesium acetate
solution, then 2µl 50 units benzonase enzyme were added before
incubation at 37◦C for 4 h. Nuclease S1 enzyme (10 µl; 200
units) was added, and the solution was further incubated at 37◦C
for 4 h. Finally, solid-phase extraction (SPE) was carried out for
these samples as follows: the cartridges were conditioned with
3ml methanol and 2ml 15mM NaCl (pH 7.4). After sample
absorption, cartridges were washed with 3ml 15mM NaCl to
remove unmodified nucleotides and modified nucleotides were
eluted from the cartridges with 2ml methanol. The solvent was
removed in a vacuum centrifuge and the dried residues were
re-dissolved in 100 µl purified water.
HPLC
The LC system consisted of an Agilent (USA) Accela HPLC
pumping system, coupled with an Accela Autosampler and
Degasser. Chromatographic separation of the DNA-adducts
was achieved by reverse phase chromatography and gradient
elution. Separation of the DNA-adducts was carried out on a
Perfluorophenyl column (Phenomenex Luna, USA), at 25◦C. The
gradient mobile phase was prepared from 1% ethanoic acid, pH
5.5 (Eluent A) and methanol (Eluent B): gradient program: 0min
95% A, 0–6min up to 95% B, 6–8min 95% B, 8–8.1min back to
95% A, 8.1–11min equilibration. The flow rate was 1 ml/min and
the injected volume was 5 µl.
TABLE 1 | MTT assay IC50 values of TMZ and C8-imidazotetrazine analogs 377
and 465 against human cancer cell lines.
Cell line MGMT MMR IC50 (µM) 3 days
TMZ 377 465
SNB19V – Proficient 38.01 ± 16.35 32.96 ± 10.80 14.34 ± 2.92
SNB19M + Proficient 508.84 ± 142.32 65.92 ± 7.68 31.83 ± 8.66
HCT116 + MLH1- 592.88 ± 16.10 44.23 ± 12.72 25.37 ± 2.21
T98G + Pro5ficient 286.96 ± 19.61 62.50 ± 6.93 33.09 ± 3.42
TMZ, 377, and 465 were dissolved in DMSO at a stock solution of 100mM (stored at
−20◦C) and diluted in culture medium prior to use. IC50 values of new analogs were
determined by MTT assay following 3 days of exposure and are shown as mean ± SD of
three independent experiments.
Compound Stability Test
TMZ or 377 (20 µl; 5 mg/ml) were mixed thoroughly with 80
µl pure water to make final concentration of 5.1mM for TMZ
and 4.6mM for 377 in a 37◦C incubator. At different time points
(0–48 h), samples were taken for detection, and filtered using
a 13mm 0.2µm polytetrafluoroethylene (PTFE) needle prior
to HPLC detection. The data processing was carried out with
Agilent 1260 Infinity.
UPLC-Q-TOF/MS Analysis
The Agilent 6540 UPLC-Q-TOF / MS (USA) was used with
electrospray ionization for DNA adducts qualitative detection.
Chromatographic separation of DNA adducts was achieved
by reverse phase chromatography and gradient elution. The
detection conditions of UPLC were the same as those for HPLC.
Analysis was performed on a triple quadrupole time of flightmass
spectrometer, fitted with a heated electrospray ionization source
Jet Stream operating in the positive ion mode with the following
working conditions: dry gas N2 temperature of 350
◦C and flow
rate of 9 l/min; nebulizer pressure of 40 psig; capillary voltage of
3,500V; nozzle voltage of 1,000V; fragmentor voltage of 135V;
secondary mass spectral collision pool voltage of 20V. For full
MS investgations, scans range from 10 to 500 m/z using a scan
rate of 10 spetra/s. Finally, data processing was carried out with
MassHunter software.
Statistical Analysis
Statistical significance was determined using Students’ t-test
analyses. P ≤ 0.05 was considered significant.
RESULTS
Growth Inhibition
The activity of TMZ and analogs 377 and 465 was tested against a
pair of isogenic human GBM cell lines: SNB19V (vector control)
and SNB19M (stable MGMT transfection). TMZ was active in
MGMT negative/low cell lines, with an IC50 value of 38.01µM
in SNB19V cells, but inactive in MGMT-overexpressing cells.
SNB19M cell line transfected with MGMT demonstrated 13.39-
fold inherent resistance to TMZ with a mean IC50 value of
508.84µM. As can be seen in Table 1, C8-imidazolyl 377 showed
anticancer activity in SNB19V and SNB19M cells with mean
IC50 values of 32.96µM, and 65.92µM, respectively. Methyl
imidazole analog 465 gave IC50 values of 14.34µMand 31.83µM
TABLE 2 | Clonogenic assay IC50 values of TMZ and C8-imidazotetrazine
analogs 377 and 465 against human cancer cell lines.
Compound SNB19V SNB19M IF*
TMZ 32.20 ± 10.35 854.65 ± 142.32 27
377 17.86 ± 7.30 >100 >6
465 14.34 ± 2.92 31.83 ± 8.66 2
IC50 values of TMZ and new analogs were determined by colony-formation assay following
11 days incubation after compound treatment (16 h) and are shown asmean± SD of three
independent experiments, IF *: SNB19M IC50 value/SNB19V IC50 value.
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FIGURE 2 | C8-imidazotetrazine analogs 377 and 465 induce cancer cell DNA damage. (A) Induction of γH2AX foci in HCT116 cells following exposure to 377 and
465. HCT116 cell was treated with vehicle control, 50µM 377 and 465 for 3, 9, 12, and 24 h; (B) Foci of treated HCT116 cells were quantified by densitometry
(Continued)
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FIGURE 2 | (Image J software). (C) Induction of γH2AX foci in T98G cells. T98G cells were treated with vehicle control, 100µM 377 and 465 for 3, 6, and 12 h, then
immunocytochemically labeled with γH2AX antibody and the secondary antibody Alexa Fluor 488; DNA was counterstained with DAPI. (D) γH2AX quantification was
performed by the ratio of DNA damaged cells to total T98G cells (cellular foci number > 10 was considered to be damaged cell). (E) Pulsed-field gel electrophoresis
(PFGE) directly detected DSBs in HCT116 cells. HCT116 cells were treated with TMZ (100µM), 377 (100µM), 465 (50µM), and DDP (10µM, as a positive control) for
24 and 48 h. (F) Detection of total γH2AX expression by Western blot. T98G cells were treated with TMZ, 377, or 465 (50 and 100µM) for 6, 12, 24, and 48 h. (G)
Detection of DNA cross-linking by alkaline gel electrophoresis. The double strand DNA was incubated with 1, 10, and 20µM TMZ, 377, and 465, DDP (cisplatin)
(10µM) was used as a positive control. The arrow marked the cross-linked DNA.
in SNB19V and SNB19M cells, respectively. In addition, 377 and
465 showed good anticancer activity against the T98G GBM cell
line which maintains inherently high MGMT expression, with
IC50 values of 62.50µM and 33.09µM, respectively. Therefore,
MGMT expression whilst conferring marked resistance to TMZ,
conferred only ∼2-fold resistance to 377 and 465. Furthermore,
the MMR-deficient HCT116 CRC cell line, resistant to TMZ
(IC50 values> 500µM), responded to 377 (IC50 value 44.23µM)
and 465 (IC50 value 25.37µM). Consistently, methylimidazole
analog 456 demonstrated∼twice the potency of imidazolyl
analog 377.
In vitro, the antitumor activity of TMZ derivatives was
further corroborated by clonogenic assays. As shown in
Table 2, compared to SNB19V cells (IC50 value 32.2µM),
SNB19M cells demonstrated ∼27-fold inherent resistance to
TMZ (IC50 value 854.65µM) following 11 days exposure of
SNB19V and SNB19M cells to TMZ. Compared to SNB19V
cells (IC50 value 17.86µM), SNB19M cells showed > 6-fold
resistance to C8-imidazole analog 377 (IC50 value > 100µM).
C8-methylimidazole analog 465 exerted potent inhibition of
colony formation in SNB19V cells (IC50 value 14.34µM)
and moreover, potent anti-clonogenic activity against MGMT-
expressing SNB19M cells (IC50 31.83 µM).
These results indicate that novel imidazolyl and
methylimidazole imidazotetrazinones 377 and 465 inhibit
the growth of tumor cells irrespective of MGMT and MMR;
of note, 465 demonstrated superior activity (∼2-fold) against
TMZ-resistant cells guiding compound concentration selection
in further experiments.
Generation of DNA Double-Strand Breaks
by Imidazotetrazine Analogs
TMZ generates O6-MeG adducts which trigger futile cycles of
mismatch repair (MMR) in MMR-proficient cells that ultimately
lead to lethal DNA double-strand breaks (DSBs). DSBs induce
rapid phosphorylation of Ser139 at the carboxy terminus of
histone H2AX, namely γH2AX; γH2AX has become the “gold
standard” marker of DNA DSBs. In order to determine whether
377 and 465 evoke DNA DSBs, the formation of γH2AX
foci was examined in HCT116 cells treated with 377 (50
and 100µM) and 465 (20 and 50µM) and visualized by
immunofluorescence microscopy following 3, 9, 12, and 24 h
exposure. Representative foci in HCT116 cells are shown in
Figure 2A and foci quantification of treated cells is shown in
Figure 2B. As demonstrated, new analogs 377 (50 and 100µM)
and 465 (20 and 50µM) induce time- and concentration-
dependent DNA DSBs in HCT116 cells. In addition, T98G cells
were treated with 100µM 377 and 465 for 3, 6, and 12 h, cellular
γH2AX foci increased time-dependently (Figures 2C,D).
Moreover, pulsed-field gel electrophoresis (PFGE) was
adopted to detect genomic DNA DSBs. HCT116 cells were
treated with TMZ (100µM), 377 (100µM), 465 (50µM), or
DDP (cisplatin, 10µM; positive control) for 24 and 48 h, and
disruption of genomic DNA was detected by PFGE (Figure 2E).
TMZ and 377 both induced DSBs in HCT116 cells and the extent
of genomic DNA breakage increased with time. Furthermore,
global γH2AX expression was examined by Western blot
following exposure of T98G cells to TMZ (100µM), 377 (50 and
100µM), and 465 (50 and 100µM) for 6, 12, 24, and 48 h. As
shown in Figure 2F, TMZ only slightly increased the expression
of γH2AX in T98G cells, whereas, the same concentration of
377 and 465 caused more extensive, time-dependent γH2AX
expression. Together these data indicate that new analogs 377 and
465 cause DNA damage in TMZ-resistant cells.
It is known that the TMZ analogmitozolomide results in DNA
cross-linking (18), which causes severe and unpredictable bone
marrow suppression (19). Therefore, we examined by alkaline gel
electrophoresis whether the TMZ derivatives caused DNA cross-
links. Double-stranded DNA was treated with 1, 10, and 20µM
TMZ, 377, and 465, DDP (1 and 10µM) was used as a positive
control; as Figure 2G demonstrates, imidazotetrazine analogs
TMZ, 377, and 465 did not lead to formation of DNA cross-links.
Cell Cycle Perturbation by
Imidazotetrazine Analogs
Futile DNA repair cycles triggered by TMZ result in cell cycle
arrest in the absence of MGMT and the presence of MMR. To
compare the effects of TMZ and analogs on cell cycle progression,
DNA flow-cytometric analyses of SNB19V and SNB19M cells
following exposure to agents (24–96 h) were performed. After
48 h treatment with 100µM TMZ, 28.7% of the SNB19V cells
arrested at G2/M (compared with 17.7% of control cells in
G2/M; Figure 3A). Further significant (P < 0.01) and prolonged
accumulation of DNA in G2/M phases was observed after 72
and 96 h of exposure (31.8 and 48.5%, respectively). In contrast,
100µM TMZ failed to perturb SNB19M cell cycle, a result
attributed to competent MGMT activity (Figure 3A).
Exposure of SNB19V cells to 377 (50µM) significantly (P
< 0.001) increased S-G2/M events by > 15% during the first
24 h period, persistent G2/M accumulation was maintained from
48 to 96 h, and a small pre-G1 peak indicative of apoptosis
induction emerged; 6.6% pre-G1 phase at 96 h (0.9% pre-G1
in control) (Figure 3B). Compared to SNB19V cells, SNB19M
cells also exhibited significant (P < 0.001) S-G2/M arrest at 24 h
exposure, but the S-G2/M block was transient—reversing ≥48 h
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FIGURE 3 | 377 and 465 caused cell cycle arrest in SNB19V and SNB19M
cells. Representative DNA histograms of SNB19V and SNB19M cells
(Continued)
FIGURE 3 | demonstrating the effects of TMZ (A), 377 (B), and 465 (C) on
cell cycle progression. Following desired exposure periods, cellular DNA was
stained with propidium iodide and analyzed by flow cytometry. Control
samples were treated with equal volume DMSO. For each sample, 10,000
events were recorded and experiments were performed in triplicate; n ≥ 3
independent trials.
(Figure 3B). Cell cycle perturbations caused by 377 (100µM)
in both SNB19V and SNB19M were similar to those elicited by
50 µM 377.
SNB19V and SNB19M cells exposed to 465 (50µM) revealed
obvious (P < 0.01) S-G2/M arrest at 24 h. Further significant
(P < 0.001) and prolonged accumulation of G2/M phase events
was observed from 48 to 72 h (38.1 and 37.3% in SNB19V; 53.0
and 48.2% in SNB19M populations, respectively; Figure 3C). The
percentage of the cell population in G2/Mwas higher in SNB19M
cells than SNB19V cells, 53.0% compared to 38.1% at 48 h and
48.2% compared to 37.3% at 72 h. Analog 465 (20µM)minimally
perturbed SNB19V and SNB19M cell cycles (Figure 3C). The
effect of TMZ derivative 465 on the cycle of MMR-deficient
HCT116 cells was also examined. It was evident that events in
G2/M accrued at both 48 and 72 h (50µM 465) while 50µM
TMZ did not interfere with the cell cycle (Figure S1). These
data indicate that TMZ analogs 377 and 465 cause cell cycle
perturbation in TMZ-resistant cells.
Induction of Apoptosis by
Imidazotetrazine Analogs
In order to further investigate the cellular effects of 377 and 465,
we characterized their impact on cell death at the molecular level.
Lysates from compound-treated cells were subjected to Western
blot analyses for expression of two apoptosis markers, caspase 3
activation, and cleaved PARP. Initially, HCT116 cells were treated
with the same concentration (50µM) of TMZ and its derivatives
for 48 h. As shown in Figure S2, we found that only 465 induced
PARP cleavage. HCT116 cells were subsequently treated with
20 and 50µM 465 for 24, 48, and 72 h. 465 induced apoptosis
in a time- and concentration-dependent manner: 20µM 465
analog induced PARP cleavage ≥48 h, however, cleaved PARP
was detected in lysates of cells treated with 50µM 465 ≥24 h
(Figure 4A). In addition, 50µM 465 also led to cleaved caspase
(48 and 72 h). In addition, MGMT-overexpressing T98G cells
were also exposed to 100µM TMZ, 50, and 100µM 377 and
465 for 24 and 48 h. As shown in Figure 4B, neither significant
caspase 3 nor PARP cleavage were induced by TMZ, 377,
or 465 cells after 24 h. However, cleaved PARP was detected
≥48 h by 50µM 377 and 465, and 100µM TMZ. These data
indicate that analogs 377 and 465 cause apoptosis in TMZ
resistant cells.
To corroborate this conclusion, changes in HCT116
cells mitochondrial membrane potential was determined
after exposure of cells to 465 (20). As shown in Figure 4C,
when HCT116 cells were treated with 10, 20, and
50µM 465 for 9 h; the JC-10 monomer signals increased
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FIGURE 4 | Induction of apoptosis by C8-imidazotetrazine analogs 377 and 465. Detection of apoptosis proteins (PARP and caspase 3) by Western blot in (A)
HCT116 cells and (B) T98G cells following treatment of cells with different concentrations TMZ, 377, or 465 for 24, 48, or/and 72 h. (C) HCT116 cells were
dye-loaded with JC-10 dye-loading solution along with 10, 20, and 50µM 465 for 9 h. The fluorescent intensities for both J-aggregates and monomeric forms of
JC-10 were measured by flow cytometry using FL1 (green) and FL2 (red) channels. Data were analyzed using C6 software. (D) Quantitative assessment of JC-10
monomer signals. (*P < 0.05, **P < 0.01).
significantly (P < 0.05) in a concentration-dependent
manner (Figures 4C,D).
Hydrolysis of Imidazotetrazine Analog 377
Under physiological conditions, TMZ is able to hydrolyze to
form MTIC which rapidly breaks down to form diazomethane
and 5-aminoimidazole-4-carboxamide (AIC); diazomethane
causesmethylation of DNA, leading to cell death.We hypothesize
that 377 could ring-open and alkylate DNA like TMZ, resulting
in DNA damage to tumor cells and subsequent apoptosis.
Analog 377 was dissolved in water, incubated at 37◦C and
analyzed by HPLC. As shown in Figure 5A, three peaks were
observed at retention times tR = 2.12min, tR = 2.43min, and
tR = 4.43min. The hydrolyzate of 377 was then identified
using a highly sensitive UPLC-Q-TOF/MS. As shown in
Figure 5B, the absorption peaks can be detected in the total ion
flow chromatogram. They were the intermediate, metabolite
and absorption peaks of 377.The structures were assigned
on the basis of UPLC-Q-TOF/MS data. The absorption
peak of 377 had a retention time of 3.568min and an ion
[M+H]+at m/z 218.0786, indicating that the molecular formula
was C8H7N7O. The intermediate had a retention time of
1.448min and an ion [M+H]+at m/z 192.0992, indicating
that the molecular formula was C7H9N7. The metabolite had
a retention time of 1.999min and exhibited an ion [M+H]+at
m/z 150.0772, indicating that the molecular formula was
C6H7N5 (Figures 5C–E). Therefore, we speculate that (similar
to TMZ) 377 can undergo hydrolysis. These data indicate
that 377 is rapidly hydrolyzed to form the intermediate
5-(3-methyltriazen-1-yl) imidazole-4-imidazole under
physiological conditions, and then undergoes further hydrolysis
to form 5-aminoimidazole-4-imidazole and a diazonium
ion (Figure 5F).
Stability of Imidazotetrazine Analog 377
The stability of 377 in H2Owasmonitored by HPLC. TMZ or 377
solutions (1 mg/ml) were incubated at 37◦C for 0–48 h. As shown
in Figure 6A, TMZ was readily hydrolyzed at 37◦C, and almost
completely hydrolyzed to form AIC at 48 h. The intermediate
product MTIC was very unstable and the absorption of MTIC
could not be detected by UV detector. The peak area of TMZ
decreased from 2,758 mAU∗s to 475 mAU∗s at 37◦C between
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FIGURE 5 | Decomposition of C8-imidazotetrazine analog 377. (A) Chromatogram of 377 by HPLC. (B) Total ion chromatogram of 377 by UPLC-Q-TOF/MS. (C)
Mass spectra of 377 (C8H7N7O) at m/z 218.0786. (D) Mass spectra of intermediate (C7H9N7) at m/z 192.0992. (E) Mass spectra of metabolite (C6H7N5) at m/z
150.0772. (F) Reaction scheme for the decomposition of 377 in H2O.
0 and 24 h, reaching 50% after 10 h. The absorption peak of
TMZ could not be detected at 48 h, but the absorption peak of
AIC increased with time (Figure 6B). However, the peak area of
377 at 37◦C decreased from 279 mAU∗s to 0 mAU∗s over 20 h,
reducing to 50% after 6 h. The peak of 377 could not be observed
at 20 h (Figures 6C,D), correspondingly, the peak areas of the
intermediate and hydrolysate accumulated over time (0–20 h):
from 87 mAU∗s to 518 mAU∗s and from 21 to 2,491 mAU∗s,
respectively. These dat suggest that 377 hydrolyzes more rapidly
than TMZ, and the intermediate is more stable than that of
TMZ (MTIC).
DNA Adducts of Imidazotetrazine
Analog 377
To investigate DNA adducts of 377, calf thymus DNA (ctDNA)
was incubated with 377 in vitro and the resulting modifications
were enzymatically cleaved with benzonase and nuclease S1.
Compared with the chromatograms of 377 and ctDNA alone,
four new absorption peaks were observed at retention times
tR = 5.241, tR = 5.418, tR = 5.702, and tR = 5.885
by HPLC analysis (Figures 7A–C). We speculated that DNA
adducts may be formed. As described above and shown
in Figure 5F, 377 can ring-open to form an intermediate
which then further breaks down to a reactive diazonium,
we posit that the diazonium will alkylate DNA. Therefore,
UPLC-Q-TOF/MS was used to analyze the structures of DNA
adducts. As shown in Figure 8A, new absorption peaks in
the total ion current profile and the UV absorption pattern
are apparent.
Upon analysis, the following deoxynucleotide adducts
were identified: N3-MeA (tR = 2.305min), [M+H]
+ ion
at m/z 152.0577, molecular formula C6H9N5; N7-MeG (tR
= 1.654min), [M+H]+ ion at m/z 168.0877, molecular
formula C6H9N5O, which gave rise to a fragment ion at m/z
151.3526 and showed the loss of a –CH3; O6-MeG (tR =
1.654min), [M+H]+ ion at m/z 168.0880, molecular formula
C6H9N5O–gave rise to a weak fragment ion at m/z 151.2436
but demonstrated no loss of –CH3, thus is the basis for the
distiction between N7-MeG and O6-MeG; N3-MeT (tR =
5.043min), [M+H]+ ion at m/z 141.0663, molecular formula
C6H8N2O2; N3-MeC (tR = 7.547min), [M+H]
+ ion at m/z
324.0930, molecular formula C6H18N3O7P; N3-MeA (tR =
7.012min), [M+H]+ ion at m/z 348.1042, molecular formula
C11H18N5O6P (Figures 8B–F).
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FIGURE 6 | The stability of TMZ and 377. (A) The UV absorption spectra of TMZ, TMZ was incubated at 37◦C for different times. (B) Quantitative peak area of TMZ.
(C) The UV absorption spectra of 377, 377 was incubated at 37◦C for different times. (D) Quantitative peak area of 377.
DISCUSSION
Temozolomide plays a key role in GBM therapy; indeed,
radiotherapy, and concomitant and adjuvant chemotherapy
with temozolomide is the standard of care for this devastating
malignancy. TMZ has also been used in the treatment of
other cancers (e.g., malignant melanoma) (21), but the ultimate
benefit is limited by inherent, or emergence of resistance.
Expression of the DNA repair protein MGMT accounts for
TMZ resistance; inactivation or down-regulation of MMR
leads to acquired tolerance to TMZ-induced lesions (2, 7)
and moreover, TMZ exposure can promote a hypermutator
phenotype (22). Therefore, developing new TMZ derivatives
which can overcome TMZ-resistance may provide significant
therapeutic advantage.
A variety of TMZ derivatives has been previously reported
(13–17, 23–28). The most common modification sites for these
analogs are at the N3 or C8 positions of TMZ. Among them,
N3-modified TMZ analogs can be divided into two categories:
one class of derivatives involves incorporation of groups to link
two TMZmolecules through the N3 site, for example, derivatives
DP68 are two TMZ molecules linked together by methylaniline.
DP68 binds two DNA strands together by hydrolysis to cross-link
the DNA and thus kill the cells (23). Another class of analogs
results from replacement of the methyl group at the N3 position
with substituents, such as chloromethyl or propargyl. These
derivatives allow the new group to alkylate DNA, thereby
exerting a cytotoxic effect (13, 14). In addition, C8-modified
TMZ analogs can also be divided into two categories: one class
may be derived through conjugation of two TMZ molecules
through the C8 position. For example, the analog 2T-P400
links two TMZs by polyethylene glycol, thereby enhancing the
solubility and stability of TMZ (24). Another type of derivative
may be formed following replacement of the C8 carboxamide
group of TMZ by another group. For instance, NEO212 is
a covalent bond of perillyl alcohol to the C8 site of TMZ,
thereby enhancing the efficacy of TMZ (25–27), while TMZ
hexyl ester which incorporates a hexyl ester bound to the C8
site of TMZ can improve TMZ skin delivery and antitumor
potency (28). In addition, other C8-substituted derivatives such
as 8-cyano-imidazotetrazine and 8-thiotemozolomide have been
developed, but their antitumor mechanism(s) remain to be
defined (17).
In this study, the anti-cancer activity of two novel C8-
substituted TMZ analogs C8 imidazolyl (377) and C8 methyl
imidazole (465) has been evaluated. Isogenic GBM cell
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FIGURE 7 | Chromatogram of 377 with ctDNA by HPLC. (A) Chromatogram of 377. (B) Chromatogram of ctDNA. (C) Chromatogram of 377 with ctDNA.
lines, SNB19V (vector control), and SNB19M (stable MGMT
transfection), were used to detect the activity of TMZ and
its derivatives. TMZ is active in the MGMT-low cell line,
with a mean IC50 value of 38.01µM, but inactive in MGMT-
overexpressing SNB19M cells, with a mean IC50 value of
508.84µM. SNB19M cells overexpressing MGMT revealed
13-fold resistance to TMZ (Table 1). However, TMZ analogs
377 and 465 demonstrate activity in SNB19 GBM cell
lines, irrespective of MGMT activity. Moreover, relative to
TMZ, 377, and 465 show greater potency (∼5–24-fold) in
MGMT overexpressing glioma T98G and MMR deficient CRC
HCT116 cells.
These results may indicate that C8 imidazolyl or
methylimidazole confer properties such as greater stability
or more efficient delivery than the carboxamide on the
imidazotetrazine. Intriguingly, in clonogenic assays, after brief
(16 h) exposure of cells to inidazotetrazine analogs, we found
that the IC50 value of 377 against SNB19M cells was at least
6-fold greater than that in SNB19V cells, while the activity of 465
against SNB19M (compared with SNB19V) cells was only 2-fold
greater (Table 2). These data suggest that the lesions imparted by
377 can be repaired by MGMT over time, whereas inclusion of a
methyl group within the C8 imidazolyl (465), imparts structural
changes that lead to more stable DNA adducts, less susceptible to
MGMT repair.
TMZ exerts cytotoxicity primarily through O6-MeG,
which triggers ineffective cycles of MMR, stalled replication
forks and lethal DNA double-strand breaks, leading to cell
death by autophagy or apoptosis (2, 4). We found through
immunofluorescence, that new analogs 377 and 465 can
induce DSB in T98G and HCT116 cells after 6 h treatments
(Figures 2A,C). Further study found that TMZ and analogs
could induce DSBs in HCT116 and T98G cells. The lower
concentration of 465 (50µM) in HCTl16 cells can result in DNA
damage equal to, or greater than that inflicted by the higher
concentration (100µM) of TMZ and 377 (Figure 2D). γH2AX
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FIGURE 8 | Mass spectra of 377. The incubation of 377 with ctDNA for 24 h followed by enzymatically digestion with benzonase and nuclease S1. (A) Total ion
chromatogram of 377 with ctDNA. (B) Mass spectra of N3-methyladenine (C6H9N5) at m/z 152.0577. (C) Mass spectra of N7-methylguanine and O6-methylguanine
(C6H9N5O) at m/z 168.0877 and 168.087. (D) Mass spectra of N3-methylthymine (C6H8N2O2) at m/z 141.0663 141. (E) Mass spectra of N3-methylcytidine
deoxynucleotides (C6H18N3O7P) at m/z 324.0930. (F) Mass spectra of N3-methyladenine deoxynucleotides (C11H18N5O6P) at m/z 348.1042.
expression in T98G cells was also examined; compared with
TMZ, the same concentration of 377 and 465 can upregulate
the expression of γH2AX (Figure 2E). Moreover, we found that
unlike the TMZ analog mitozolomide, TMZ derivatives 377
and 465 did not produce DNA cross-links (Figure 2F) that can
cause serious side effects such as myelosuppression. These results
indicate that analogs 377 and 465 can evoke DNA damage in
TMZ-resistant cells without leading to DNA cross-linking. We
found that TMZ analogs 377 and 465 can lead to G2/M arrest
irrespective of MGMT status, and 465 had a greater effect on the
cell cycle of MGMT highly-expressing SNB19M cells (Figure 3).
Analog 465 also caused G2/M block in HCT116 cells (Figure S1).
In addition, combined evidence strongly suggests that C8 analogs
377 and 454 induce apoptotic cell death in TMZ-resistant
(MGMT+; MMR-deficient) cells evidenced by sub-G1 cell
cycle events (Figure 3), PARP cleavage, caspase activation, and
enhanced JC-10 monomer detection (Figure 4). Mitochondrial
membrane potential changes indicate that TMZ derivatives
may lead to apoptosis dependent on mitochondrial pathways.
Together, these data demonstrate that novel C8-substitured
TMZ analogs can circumvent TMZ resistance in CRC and
GBM cells.
Experiments were undertaken to determine mechanistic
activation of C8 analogs, and whether (like TMZ) they act
as prodrug vehicles ultimately delivering a toxic methyl lesion
to O6-guanine. We established that TMZ analog 377 ring-
opens and is rapidly hydrolyzed under physiological conditions
to form the intermediate 5-(3-methyltriazen-1-yl) imidazole-
4-imidazole (MTII), MTII possesses markedly greater stability
than MTIC (the hydrolysis intermediate of TMZ), producing
5-aminoimidazole-4-imidazole and diazonium (Figure 5F). The
reactive diazonium produces methylated DNA lesions at multiple
sites including N3-MeA, N7-MeG, and O6-MeG (Figures 8B,C).
Thus, as shown in (Figures 6A–C), 377 hydrolysis is faster
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than TMZ, and the intermediate is more stable which may
explain why 377 exerts activity in TMZ-tolerant or -resistant
HCT116 and T98G cells. However, long term, the damage
accrued from exposure of cells to 377 can be repaired by MGMT
and 377 activity is therefore attenuated (Table 2, Figure 3B), as
supported by clonogenic assays. Therefore, replacement of C8
carboxamide by imidazolyl (377) and methyl imidazole (465)
may enhance stability of intermediates which might induce
DNA damage and apoptosis in MGMT overexpressing and
MMR deficient CRC cells. Unfortunately, analyses of stability,
and DNA adduct formation by analog 465 was thwarted
by precipitation which occurred during incubation of 465
with ctDNA.
In summary, novel C8-substituted TMZ analogs 377 and
465 elicit in vitro antitumor activity irrespective of MGMT
and MMR status. DNA DSBs were generated in MGMT-
overexpressing glioma SNB19M and T98G cells and MMR
deficient CRC HCT116 cells. TMZ derivatives perturbed
and arrested SNB19V and SNB19M cell cycle progression.
Moreover, compared to TMZ, analogs 377, and 465 were
able to induce more extensive apoptosis in HCT116 and
T98G cells. Similar to TMZ, analog 377 undergoes to ring
opening and hydrolysis leading to DNA adducts formation
which likely underlies the anticancer effects. These analogs
may offer potential for TMZ-resistant GBM and broader
spectrum malignancies.
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